Understanding Bipolar Disorder with Pharmacogenetic Testing

Living with bipolar disorder often means working with your care team to find medications that keep your mood steady with side effects you can live with. This guide explains what pharmacogenetic (PGx) testing can tell you about common bipolar treatments, where the evidence is strong, where it is limited, and how to use results safely.

Bipolar disorder is another psychiatric illness where disturbances related to mood, energy, and activities prevail. A person may experience intense mania and even deep depression with this type of mental illness. Therefore, such mood swings make it hard to balance life. Luckily, treatment for bipolar disorder keeps improving, and one tool that can help guide medication choices is PGx testing. PGx testing does not diagnose bipolar disorder; it looks at how your genes affect the way you process medicines. In this blog, we will explore bipolar disorder with Pharmacogenetic Testing

What is Pharmacogenetic Testing?

Pharmacogenetic testing is a test that enables you to know how your genetics may influence the way your body reacts to medication. As such, nobody’s body is alike; everything works well, not in everybody. Hence, the test will help the doctors understand which medicines will work the best for you based on your genetic makeup. Thus, this may minimize some trials and errors regarding developing the proper treatment.

Why Do You Need (PGx) gene test for bipolar disorder?

Most of the time, bipolar needs medication to steady out the symptoms. The challenge is finding the right medicine. What works for one person may not work for another. PGx gene test for bipolar disorder can reduce some of the guesswork when figuring out which medicine may be right for you. It also equips your doctor with a report about how your body might react to certain medicines, which may help speed up the process.

How Does the (PGx) Gene Test Work?

The PGx gene test is non-invasive and straightforward. You collect a simple cheek (buccal) swab and send it to the lab. They would run it in the test to scan for any specific genes and return results that show how your body metabolizes medication for presentation to your doctor. Your doctor can then use this information, along with your history and other factors, when choosing medicines for your bipolar disorder.

The test does not diagnose bipolar disorder, but you can order an at-home pharmacogenetic test for bipolar disorder medications with the RPh Labs PGx testing kit. Visit our website at RPH Lab – Online Testing Labs – Pharmaceutical Testing Kits to get Pharmacogenomic Testing Kits at affordable prices.

Benefits of Pharmacogenomic Testing Kits for Bipolar Disorder

1. Tailor-made therapy: Your prescriber can consider your genetic makeup when choosing drugs and doses.
2. Quick response: Finding the right drug within a shorter time frame makes one feel better sooner.
3. Less medication trial and error: The test may help you avoid some medications that are less likely to work or more likely to cause side effects, which can help physicians choose a suitable medicine sooner.
4. Support for mood stability: When the test helps your doctor find a well-tolerated, effective medication sooner, it may support a more stable mood with fewer extremes of bipolar symptoms.

Who Should Take the Pharmacogenomic Testing Kits?

Especially, in case you have been diagnosed with something more serious, like bipolar disorder and haven’t found the proper medication, pharmacogenomic testing kits may help your prescriber choose a suitable prescription. Besides, it’s perfect for those in the early stages of the treatment process who do not want to fall into the trap of trying.

A PGx test is not a test for bipolar disorder

It is worth being clear from the start. A pharmacogenetic test does not diagnose bipolar disorder, and it cannot tell you whether you have it. Diagnosis comes from a clinical evaluation by a psychiatrist or other qualified clinician, based on your symptoms, history and course over time.

What PGx testing does is look at genes that affect how your body handles certain medications. For some drugs, a result can suggest a lower dose, a different option, or extra caution. For others, genes add little, and blood levels, kidney and liver function, and other medicines matter much more.

That distinction shapes how you should think about testing in bipolar disorder. It is a medication tool, and it works best when your diagnosis is already established and your care team is choosing or adjusting treatment.

For a trusted overview of symptoms and treatment, see the NIMH bipolar disorder page. For the basics of how PGx works, read what PGx testing is.

Mood stabilizers and what genes can predict

Mood stabilizers are the foundation of treatment for many people, but they differ a lot in how much genetics can help.

• Lithium is cleared by the kidneys, not by the liver enzymes most PGx panels test. There is no CPIC dosing guideline for it. Regular blood level checks, kidney and thyroid monitoring, hydration and drug interactions remain the key safety tools.
• Valproate (divalproex) carries an FDA warning for people with mitochondrial disorders caused by POLG gene variants. This is usually checked when there is a clinical reason, not as part of a routine medication panel.
• Lamotrigine has no CPIC dosing guideline. Its rash risk is managed mainly by starting low and increasing slowly, and by watching for interactions such as valproate, which raises lamotrigine levels.
• Carbamazepine and oxcarbazepine have the strongest gene evidence of the mood stabilizers, covered in the next section.

So if you mainly take lithium or lamotrigine, a PGx panel will tell you little about those drugs specifically. It may still be useful for other medicines you take now or in the future, including antidepressants, antipsychotics and drugs for pain or heart health.

Never stop or change mood stabilizers on your own. Sudden changes can raise the risk of relapse.

Carbamazepine genetic testing and serious skin reactions

Carbamazepine is used for some people with bipolar disorder, and it has one of the best-known gene-drug safety links in medicine. People who carry the HLA-B*15:02 variant have a much higher risk of Stevens-Johnson syndrome and toxic epidermal necrolysis, rare but life-threatening skin reactions.

The carbamazepine label carries a boxed warning recommending HLA-B*15:02 screening before starting the drug in people with ancestry from populations where the variant is more common, especially many parts of Asia. Oxcarbazepine has a related warning. A second variant, HLA-A*31:01, is linked to other carbamazepine hypersensitivity reactions. Both are listed in the FDA table of pharmacogenetic associations.

It is important to know that HLA-B and HLA-A are not among the 20 genes on the RPh Labs panel. Carbamazepine genetic testing for these variants is usually ordered as a separate test by your prescriber, ideally before the first dose.

Carbamazepine also speeds up CYP3A4 and other enzymes. That can lower levels of many other drugs, including some antipsychotics and hormonal birth control, so a full medication review matters as much as carbamazepine genetic testing.

Antipsychotics for bipolar and the CYP2D6 gene

Several newer antipsychotics for bipolar symptoms are used alone or alongside mood stabilizers. Some of them have clear gene guidance in their FDA labels.

• Aripiprazole: the label recommends about half the usual dose for known CYP2D6 poor metabolizers, with further changes if strong CYP3A4 inhibitors are also used.
• Brexpiprazole: the label also recommends a lower dose for CYP2D6 poor metabolizers.
• Risperidone: processed partly by CYP2D6, although the active metabolite limits how much the gene changes overall effect.
• Quetiapine, lurasidone and cariprazine: depend mainly on CYP3A4. Drug interactions with strong CYP3A4 inhibitors or inducers are usually a bigger concern than your genes.

For antipsychotics for bipolar disorder, a CYP2D6 result can help your prescriber set a safer starting dose and interpret side effects such as restlessness or sedation. It does not predict whether a drug will control mood episodes.

Remember that some antidepressants, such as fluoxetine, paroxetine and bupropion, block CYP2D6. Taking them can make a normal metabolizer act like a poor one, which is called phenoconversion. Our guide to CYP2D6 inhibitors explains more.

Antidepressants in bipolar disorder need extra care

Depressive episodes are often the hardest part of bipolar disorder, and antidepressants are sometimes part of treatment. They are generally used with caution and usually alongside a mood stabilizer or antipsychotic, because in some people they may trigger a switch into mania or faster cycling.

PGx testing applies to these drugs in the same way it does for depression. CYP2C19 affects escitalopram, citalopram and sertraline. CYP2D6 affects paroxetine, fluvoxamine, venlafaxine and many tricyclics. A result can help your prescriber choose a dose or pick a drug that fits your metabolism.

What testing cannot do is predict whether an antidepressant will trigger mania. That risk is judged clinically, based on your history and how your mood responds. Watch for early signs such as less need for sleep, racing thoughts or unusual energy, and report them promptly.

Our article on genetic testing for antidepressants covers these gene-drug links in more detail.

What a PGx panel can show about your bipolar medication

A broad panel is most useful when you take, or may take, several medications. For bipolar medication decisions, these genes are the most relevant:

• CYP2D6: aripiprazole, brexpiprazole, risperidone and several antidepressants.
• CYP2C19: SSRIs such as escitalopram and sertraline, and some anxiety medicines.
• CYP3A4 and CYP3A5: context for drugs cleared by these enzymes, where interactions often matter more than genes.
• CYP2C9: relevant to phenytoin and some pain relievers, useful if you take other medicines.

The RPh Labs 20-gene panel covers these enzymes and reports on 240+ medications. Because many people with bipolar disorder also take medicines for sleep, pain, blood pressure or cholesterol, the same result can help with prescriptions outside mental health too. You can browse the medication list by gene to see what is included.

The report will not cover lithium dosing, lamotrigine rash risk or HLA-B screening for carbamazepine. Knowing what a bipolar medication report leaves out is as important as knowing what it includes.

Who may benefit from testing

Testing is not needed for everyone with bipolar disorder. It tends to add the most value in these situations:

• You have had strong side effects at low or standard doses of an antipsychotic or antidepressant.
• A medication seemed to do nothing at a full dose, and levels or adherence do not explain it.
• Your prescriber is considering aripiprazole, brexpiprazole or an antidepressant with CYP2D6 or CYP2C19 guidance.
• You take several medications and want a clearer view of possible interactions.
• You want one result to guide prescriptions for years, since your genes do not change.

It is less likely to change decisions if you are stable on lithium alone, or if your main question is about lamotrigine. Even then, some people choose to test so the information is ready if treatment changes later.

The best person to weigh this with you is your prescriber, who knows your history and current plan.

Keep a simple medication and mood log

Gene results are most useful when your care team can match them to what actually happened with each drug. A simple log makes that much easier, and it only takes a few minutes a day.

Track these details in a notebook or phone app:

• Each medication, the dose and the date of every change.
• Your mood each day on a simple scale, plus hours of sleep.
• Side effects such as drowsiness, restlessness, tremor, weight change or stomach upset, and when they started.
• Missed doses, new over-the-counter products, alcohol and big changes in caffeine or smoking.

Bring the log and your PGx report to appointments together. If you are a CYP2D6 poor metabolizer and your log shows restlessness that started after a dose increase of a CYP2D6-dependent drug, that pattern gives your prescriber something concrete to act on.

A log also helps in the other direction. It can show that a side effect lines up with a new interacting drug rather than your genes. Either way, your care team decides on any change, and you should not adjust doses on your own.

Talking to your care team about results

Stability matters a great deal in bipolar disorder, so results should be used carefully and never as a reason to change treatment on your own. These steps help:

1. Share the full report with your psychiatrist or prescriber and your pharmacist.
2. Bring a complete list of medicines, supplements and any past drugs that caused problems.
3. Ask which results affect your current regimen and which are for future reference.
4. Agree on a plan before any change, including how you will monitor mood, sleep and side effects.
5. Keep up regular blood tests if you take lithium or valproate, whatever your gene results say.

A pharmacist can help translate the report. With RPh Labs, every report is reviewed by a PharmD pharmacist and a free pharmacist consultation is included. Providers can find more detail on the for providers page.

Getting a PGx test at home

If you and your prescriber decide testing makes sense, you can do it without a lab visit. The RPh Labs at-home kit uses a painless cheek swab, not blood.

• The kit ships within one business day, with free shipping both ways.
• Results arrive 7 to 10 business days after the sample reaches the lab in Dallas, Texas.
• The lab is CLIA-certified and COLA-accredited.
• Self-pay is $299, HSA and FSA eligible, with an option of 4 interest-free installments.
• Insurance, including Medicare and Texas Medicaid, is accepted for eligible patients. See the insurance page.

RPh Labs serves patients in 45 states. Reports are updated when guidelines change, so your results stay useful as the science on bipolar medication and other drugs develops.

Conclusion

PGx testing is a powerful tool for living with bipolar disorder. This helps your doctor understand your body better and makes the selection of the proper treatment more quickly. Here at RPh Labs, we offer at-home pharmacogenetic testing with every report reviewed by a PharmD pharmacist. If you have had problems with your treatment, this test might be a helpful next step to discuss with your doctor.
Contact us to learn how the RPh Labs PGx test kit can support your bipolar disorder medication plan.

Bipolar disorder PGx FAQ

Can a gene test tell me if I have bipolar disorder?

No. Pharmacogenetic testing looks at how your body processes certain medications. It does not diagnose any mental health condition. A diagnosis of bipolar disorder comes from a clinical evaluation of your symptoms, history and how your mood changes over time.

Does PGx testing help with lithium dosing?

Not directly. Lithium is cleared by the kidneys and has no CPIC gene-based dosing guideline. Dosing depends on blood levels, kidney function, hydration and interacting drugs such as some blood pressure medicines and anti-inflammatory pain relievers. Regular lab checks remain essential.

Is carbamazepine genetic testing included in the RPh Labs panel?

No. HLA-B*15:02 and HLA-A*31:01 are not among the 20 genes on the RPh Labs panel. Your prescriber can order HLA-B screening separately, ideally before carbamazepine is started, especially if you have ancestry from populations where the variant is more common.

Should I lower my aripiprazole dose if I am a CYP2D6 poor metabolizer?

Do not change it yourself. The aripiprazole label suggests a lower dose for known CYP2D6 poor metabolizers, but your prescriber will also consider your current dose, response, side effects and other drugs. Bring the result to them and agree on any change together.

Can testing predict which mood stabilizers will work for me?

Not reliably. Current guidelines do not use genes to predict response to lithium, valproate or lamotrigine. Genes mainly help with safety and dosing for certain drugs, such as carbamazepine screening and CYP2D6-guided antipsychotic doses.

Do I need to repeat a PGx test if my bipolar medication changes?

No. Your genes stay the same for life, so one result can be applied to new prescriptions. Ask your pharmacist or prescriber to check the existing report whenever a new medication is considered.